# A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder

> **NCT02741791** · PHASE3 · COMPLETED · sponsor: **Axsome Therapeutics, Inc.** · enrollment: 312 (actual)

## Conditions studied

- Treatment Resistant Major Depressive Disorder

## Interventions

- **DRUG:** AXS-05
- **DRUG:** Bupropion

## Key facts

- **NCT ID:** NCT02741791
- **Lead sponsor:** Axsome Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2020-03-20
- **Final completion:** 2020-03-20
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02741791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02741791, "A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02741791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*